ECSP056106A - Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas - Google Patents

Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas

Info

Publication number
ECSP056106A
ECSP056106A EC2005006106A ECSP056106A ECSP056106A EC SP056106 A ECSP056106 A EC SP056106A EC 2005006106 A EC2005006106 A EC 2005006106A EC SP056106 A ECSP056106 A EC SP056106A EC SP056106 A ECSP056106 A EC SP056106A
Authority
EC
Ecuador
Prior art keywords
phosphonic acid
acid compounds
inhibitors
proteasas
serina
Prior art date
Application number
EC2005006106A
Other languages
English (en)
Inventor
Michael N Greco
Harold R Almond
Garavilla Lawrence De
Michael J Hawkins
Michael J Humora
Yun Qian
Donald Gilmore Walker
Sergio Cesco-Cancian
Christopher Norman Nilsen
Mitul N Patel
Kirk Leonard Sorgi
Eugene Powell
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ECSP056106A publication Critical patent/ECSP056106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a compuestos de ácido fosfónico útiles como inhibidores de la serina proteasa, composiciones de los mismos y métodos para el tratamiento de enfermedades inflamatorias y mediadas por la serina proteasa.
EC2005006106A 2003-04-16 2005-10-14 Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas ECSP056106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/414,782 US7459461B2 (en) 2001-10-19 2003-04-16 Phosphonic acid compounds as inhibitors of serine proteases

Publications (1)

Publication Number Publication Date
ECSP056106A true ECSP056106A (es) 2006-03-01

Family

ID=33309497

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006106A ECSP056106A (es) 2003-04-16 2005-10-14 Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas

Country Status (21)

Country Link
US (17) US7459461B2 (es)
EP (1) EP1620446B1 (es)
JP (1) JP4526534B2 (es)
KR (1) KR101106574B1 (es)
CN (1) CN100475824C (es)
AU (1) AU2004232941B2 (es)
BR (1) BRPI0409566A (es)
CA (1) CA2523203C (es)
CR (1) CR8046A (es)
EA (1) EA200501463A1 (es)
EC (1) ECSP056106A (es)
ES (1) ES2399884T3 (es)
HR (1) HRP20050899A2 (es)
ME (1) MEP48608A (es)
MX (1) MXPA05011218A (es)
NO (1) NO20055396L (es)
NZ (1) NZ543139A (es)
RS (1) RS20050778A (es)
UA (1) UA80869C2 (es)
WO (1) WO2004094441A2 (es)
ZA (1) ZA200509249B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459461B2 (en) 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
KR101326537B1 (ko) * 2006-11-30 2013-11-08 (주)아모레퍼시픽 카텝신 ｇ 발현 억제제 조성물
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
SG181883A1 (en) 2009-12-25 2012-08-30 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
EP3193906B1 (en) * 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
CA3258111A1 (en) * 2022-05-30 2025-04-07 Scinnohub Pharmaceutical Co., Ltd USE OF A TETRAHYDRONAPHTYRIDINE DERIVATIVE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO ADHESION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (es) 1962-06-22
US4511551A (en) 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
AT380490B (de) * 1984-09-06 1986-05-26 Voest Alpine Ag Vorrichtung zur gewinnung der fuehlbaren waerme von schuettfaehigem heissgut
JPS61151199A (ja) * 1984-12-26 1986-07-09 Otsuka Pharmaceut Factory Inc カルボン酸アミド誘導体
US4704382A (en) * 1985-07-29 1987-11-03 G. D. Searle & Co. Phenylpiperazine phosphonates
US4822780A (en) * 1987-07-08 1989-04-18 Otsuka Pharmaceutical Factory, Inc. Carboxamide compounds
US5508273A (en) 1993-12-30 1996-04-16 Ortho Pharmaceutical Corporation Substituted phosphonic acids and derivatives useful in treating bone wasting diseases
ATE253920T1 (de) 1995-07-17 2003-11-15 Cephalon Inc Phosphor enthaltende hemmer von cystein- und serin-proteasen
EP0940400A4 (en) * 1996-10-25 2002-10-02 Mitsubishi Pharma Corp HETEROCYCLIC AMID COMPOUNDS AND THEIR MEDICAL APPLICATION
US6528514B1 (en) * 1998-03-11 2003-03-04 Welfide Corporation IgE antibody production inhibitors and autoimmune diseases inhibitors
US7459461B2 (en) 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
DK1438316T3 (da) 2001-10-19 2006-10-16 Ortho Mcneil Pharm Inc Phosphonsyreforbindelser som inhibitorer af serinproteaser
WO2007047431A2 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors

Also Published As

Publication number Publication date
US8198440B2 (en) 2012-06-12
US20040082544A1 (en) 2004-04-29
US20090118508A1 (en) 2009-05-07
US20090118235A1 (en) 2009-05-07
US8609888B2 (en) 2013-12-17
ZA200509249B (en) 2007-01-31
HRP20050899A2 (en) 2006-09-30
AU2004232941A1 (en) 2004-11-04
EP1620446B1 (en) 2012-10-24
KR101106574B1 (ko) 2012-01-19
CN1832950A (zh) 2006-09-13
AU2004232941B2 (en) 2011-07-28
WO2004094441A2 (en) 2004-11-04
NO20055396L (no) 2006-01-04
US20090118234A1 (en) 2009-05-07
MXPA05011218A (es) 2006-07-06
RS20050778A (sr) 2008-04-04
JP4526534B2 (ja) 2010-08-18
US20110092705A1 (en) 2011-04-21
US8212039B2 (en) 2012-07-03
JP2006523705A (ja) 2006-10-19
NO20055396D0 (no) 2005-11-15
UA80869C2 (en) 2007-11-12
MEP48608A (en) 2011-02-10
US8304430B2 (en) 2012-11-06
US7459461B2 (en) 2008-12-02
BRPI0409566A (pt) 2006-04-18
US20120238528A1 (en) 2012-09-20
US20110092457A1 (en) 2011-04-21
CR8046A (es) 2009-01-16
WO2004094441A3 (en) 2005-10-13
US20090124581A1 (en) 2009-05-14
EA200501463A1 (ru) 2006-08-25
US20130281407A1 (en) 2013-10-24
US20110319363A1 (en) 2011-12-29
ES2399884T3 (es) 2013-04-04
US8461195B2 (en) 2013-06-11
US8394804B2 (en) 2013-03-12
US20090118504A1 (en) 2009-05-07
KR20060006929A (ko) 2006-01-20
CA2523203C (en) 2013-06-11
US20090131671A1 (en) 2009-05-21
EP1620446A2 (en) 2006-02-01
CA2523203A1 (en) 2004-11-04
US8497373B2 (en) 2013-07-30
US20090143336A1 (en) 2009-06-04
US20090137528A1 (en) 2009-05-28
CN100475824C (zh) 2009-04-08
US20090131371A1 (en) 2009-05-21
US8703957B2 (en) 2014-04-22
US8207338B2 (en) 2012-06-26
US8247599B2 (en) 2012-08-21
US20110086819A1 (en) 2011-04-14
NZ543139A (en) 2009-02-28
US20120283221A1 (en) 2012-11-08
US8178673B2 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
CR8563A (es) Inhibidores de la quimasa novedosos
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
HRP20070078A2 (hr) Fosfonatni analozi spojeva koji inhibiraju hiv
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
PA8523001A1 (es) Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY29397A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
UY31849A (es) Nuevos compuestos como inhibidores de pde4
ECSP056106A (es) Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas
CR11873A (es) Nuevas carboxamidas heterociclicas para su uso como inhibidores de trombina
PA8616901A1 (es) Metodos y composiciones para la inhibicion de selectina
MEP48708A (en) Phosphonic acid compounds as inhibitors of serine proteases
AR039937A1 (es) Derivados de azetidina como inhibidores de tripsina proteasas
ECSP088111A (es) Derivados de 2-oxo-1,2,5,6-tetrahidropiridina inhibidores de la trombina
EA200801400A1 (ru) Новые производные индолизина, способ их получения и терапевтические композиции на их основе
PA8636801A1 (es) Procesos para la preparacion de esteres alquilicos o bencilicos del acido 2-ciano-3-naftalen-1-il-acrilico
PA8615401A1 (es) Metodos para la preparacion del acido {2-[(8,9)-dioxo-2, 6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
UY28439A1 (es) "3-nitro-pirazolo(1,5-a)pirimidinas 7-sustituidas y composiciones y métodos relacionados"
PE20130772A1 (es) Derivados de sulfonamida de 3-aminolactamas como agentes anti-inflamatorios
UY28102A1 (es) Nuevas sales
ECSP003478A (es) Aril policiclico substituido y uracilos heteroaril utiles para la inhibicion selectiva de la cascada de coagulacion
PA8636701A1 (es) Procedimientos para la preparacion de esteres alquilicos y bencilicos del acido 2-ciano-3-naftalen-1-il-3-fenil-propionico